Regulations for Good Clinical Practice Article 90

The investigator should not implement any deviation, or changes of the protocol without agreement by the sponsor and prior approval from the Ethics Committee, except where necessary to eliminate an immediate hazard(s) to trial subjects, or when the change(s) involves only administrative aspects of the trial.For a deviation, or a change of, the protocol implemented to eliminate an immediate hazard(s) to trial subjects, the investigator should submit the implemented deviation or change, the reasons for it, or the proposed protocol amendment(s) to the Ethics Committee and the sponsor, and to the Competent Authority if the trials are approved by the Competent Authority.
中文原文 藥品優良臨床試驗作業準則第90條
試驗主持人未取得試驗委託者同意及人體試驗委員會核准前,不應偏離或變更試驗計畫書之執行。
但為及時避免受試者遭受傷害或僅為行政事務之改變者,不在此限。
為及時避免受試者遭受傷害所為之偏離或變更,試驗主持人應於七日內將偏離或變更之內容及其原因,或試驗計畫書修正案,提交人體試驗委員會、試驗委託者;經主管機關核准進行之臨床試驗,應同時提交主管機關。

English translation for reference only; the Chinese text prevails. Not legal advice.